(0.31%) 5 115.89 points
(0.30%) 38 356 points
(0.35%) 15 984 points
(-0.99%) $83.02
(5.25%) $2.02
(0.30%) $2 354.30
(0.36%) $27.63
(4.11%) $960.00
(-0.28%) $0.932
(-0.47%) $10.97
(-0.59%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.04%
@ $147.38
発行日: 29 4月 2024 @ 23:32
リターン: 0.63%
前回のシグナル: 4月 27 - 04:53
前回のシグナル:
リターン: 2.28 %
Live Chart Being Loaded With Signals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference...
Stats | |
---|---|
本日の出来高 | 143 473 |
平均出来高 | 839 403 |
時価総額 | 18.75B |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $-0.750 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -42.01 |
ATR14 | $4.37 (2.94%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 0 | Common Stock |
2024-03-20 | Fitzgerald Kevin Joseph | Buy | 0 | Common Stock |
2021-02-11 | Fitzgerald Kevin Joseph | Sell | 9 000 | Performance Stock Option 2017 (right to buy) |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 16 250 | Stock Option (right to buy) |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
---|
-6.10 |
Last 99 transactions |
Buy: 237 064 | Sell: 275 392 |
ボリューム 相関
Alnylam Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
MYNA | -0.939 |
MLTX | -0.916 |
NRDS | -0.914 |
HYPR | -0.912 |
EBSB | -0.911 |
FLXN | -0.911 |
UPTD | -0.906 |
NRC | -0.903 |
MNTV | -0.901 |
STRL | -0.898 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Alnylam Pharmaceuticals 相関 - 通貨/商品
Alnylam Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $1.83B |
総利益: | $1.52B (83.02 %) |
EPS: | $-3.52 |
FY | 2023 |
収益: | $1.83B |
総利益: | $1.52B (83.02 %) |
EPS: | $-3.52 |
FY | 2022 |
収益: | $1.04B |
総利益: | $868.60M (83.73 %) |
EPS: | $-9.30 |
FY | 2021 |
収益: | $844.29M |
総利益: | $704.14M (83.40 %) |
EPS: | $-7.20 |
Financial Reports:
No articles found.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。